Authors

Latest:

Dr. Padia on the Utility of Y-90 Glass Microspheres in HCC

Siddharth Padia, MD, discusses the utility of TheraSphere™ Yttrium-90 Glass Microspheres in patients with hepatocellular carcinoma.

Evangelia Sereti, MSc, PhD

Latest:

Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Timothy Schmidt, MD, University of Wisconsin

Latest:

Rapid Readouts: IKEMA Subgroup Analysis in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics

A. Timothy Schmidt, MD, discusses data from the subgroup analysis of the IKEMA study of isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma and high-risk cytogenetics that was presented at the American Society of Clinical (ASCO) 2021 Annual Meeting.

Lance Baldo, M.D., Chief Medical Officer, Adaptive Biotechnologies

Latest:

Next-Generation Sequencing Minimal Residual Disease Testing in Blood Cancer Is Needed Now More Than Ever

Sponsored Content by Adaptive Biotechnologies

Olwen Hahn, MD

Latest:

Dr. Hahn on the Impact of Trastuzumab Emtansine in HER2+ Breast Cancer

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

Byoung Chul Cho, MD

Latest:

Dr. Cho on the Updated Efficacy of Repotrectinib in TKI-Naïve ROS1+ NSCLC

Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.

Saima Hassan MD, PhD, FRCSC

Latest:

Dr. Hassan on the Mechanism of Action of Talazoparib in TNBC

Saima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.

Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology

Latest:

ASCO 2020: Updates in Prostate Cancer Treatment

Sarah Goldberg, MD, MPH, Yale School of Medicine

Latest:

WCLC Updates in Small Cell Lung Cancer

Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.

Adam Sperling, MD, PhD

Latest:

Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple Myeloma

Adam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.

Dawn Fallik

Latest:

The Hamilton of Medicine

Most physician-scientists are intense, motivated and focused, but Keith T. Flaherty, MD, takes it to another level.

Richard Gorlick, MD

Latest:

Dr. Gorlick on the Challenges of Identifying Immunotherapeutic Targets in Osteosarcomas

Richard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.

Alice Indini, MD

Latest:

Dr. Indini on the Rationale for the PULSAR Trial in Classic Kaposi Sarcoma

Alice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.

Ghaith Abu-Zeinah, MD

Latest:

Dr. Abu-Zeinah on the Efficacy of Interferon-Alpha in Polycythemia Vera

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

Memorial Sloan Kettering Cancer Center

Latest:

Memorial Sloan Kettering Cancer Center Launches MSKCC India to Expand Access to World-Renowned Oncologists, Cancer Care, Research, and Education

Memorial Sloan Kettering Cancer Center, the world’s oldest and largest private cancer center, has launched MSKCC India to provide cancer patients in India with access to the institution’s world-renowned oncologists, research, clinical trials, and education.

Brittany F. Lees, MD

Latest:

Dr. Lees on the Utility of Genetic Testing in Ovarian Cancer

Brittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.

Alessandro Gronchi, MD

Latest:

Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.

Daniel Keifenheim, PhD

Latest:

Novel Tubulin-Targeting Therapies Make Headway

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.

Kent Hoskins, MD

Latest:

Dr. Hoskins on the Impact of Race on Breast Cancer Outcomes

Kent Hoskins, MD, discusses the impact of race on breast cancer outcomes.

Emily C. Ayers, MD

Latest:

Dr. Ayers on the Evolving Treatment Landscape in CLL

Emily C. Ayers, MD, hematologist/oncologist, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.